Photobiomodulation for the management of xerostomia and oral mucositis in patients with cancer: a randomized clinical trial

• DOI: 10.1007/s10103-023-03760-y
• Publication Date: 2023-04-15T06:02:16Z
• Authors: Roberta Mariano d...; Fausto Medeiros M...; Giovanna Rosa Deg...; Sérgio Luiz Pinheiro
• Keywords: Stomatitis; Head and Neck Neoplasms; Quality of Life; Humans; Saliva, Artificial; Low-Level Light Therapy; Xerostomia; 3. Good health

To evaluate the applicability of photobiomodulation therapy (PBM-T) in the management of xerostomia and OM. Fifty-three patients with head and neck squamous cell carcinoma were randomized into two groups: Sham and PBM-T. The Sham group received artificial saliva and laser simulation, while the PBM-T group received artificial saliva and PBM-T. Xerostomia-related quality of life (QoL), the presence or absence of OM lesions, the decayed-missing-filled teeth (DMFT) index, and periodontal charts were evaluated. The results of the QoL questionnaire, DMFT index, and periodontal chart were analyzed with the Kruskal-Wallis test, followed by the Student-Newman-Keuls test, while OM findings were compared using the Mann-Whitney test. QoL scores significantly increased in the Sham group (p < 0.0001), denoting more severe xerostomia symptoms (p = 0.0074), and decreased in the PBM-T group, indicating no or very mild xerostomia. Higher grades of OM were found in the Sham group than the PBM-T group (p = 0.0001). There was no significant difference in DMFT index or periodontal charts between the groups (p > 0.05). PBM-T improved QoL in patients with head and neck cancer treated with radiotherapy, whether as radiation alone or as an adjunct to chemotherapy and surgery.